Aim
To compare dosing patterns of canakinumab in pediatric and adult CAPS patients of a predominantly Western population (WP) vs Japanese patients (JP). Figure 1 Step-wise up-titrations in patients (WP and Japanese) who did not achieve or remain in complete response
Methods
Canakinumab s.c. 150 mg (if >40 kg) or 2 mg/kg (if ≤40 kg) was dosed every 8 weeks.
Step-wise up-titrations in dose were allowed in patients who did not achieve/ remain in complete response (CR, Figure 1 ).
Results
Median 
Conclusions
Increased doses of canakinumab were equally efficacious in patients of a WP and Japanese population comprising different CAPS phenotypes without evidence of a change in AE profile. These data suggest that children and patients with more severe CAPS phenotypes, irrespective of ethnicity, require differential dosing. 
